Table 2 CD14 genotype distribution in the Dutch Caucasian STD cohort.
CD14 -260 C>T | ||||||||
|---|---|---|---|---|---|---|---|---|
1.1 (CC) | 1.2 (CT) | 2.2 (TT) | ||||||
Total | n | % | n | % | n | % | ||
Total | 217 | 66 | 30,4% | 107 | 49,3% | 44 | 20,3% | |
CT IgG+ | LCx+ (CT DNA+) | 135 | 38 | 28,1% | 69 | 51,1% | 28 | 20,7% |
MO+ | 42 | 12 | 28,6% | 24 | 57,1% | 6 | 14,3% | |
Symp | 56 | 14 | 25,0% | 31 | 55,4% | 11 | 19,6% | |
LAP+ | 17 | 4 | 23,5% | 10 | 58,8% | 3 | 17,6% | |
LCx- (CT DNA-) | 82 | 28 | 34,1% | 38 | 46,3% | 16 | 19,5% | |
MO+ | 29 | 12 | 41,4% | 11 | 37,9% | 6 | 20,7% | |
Symp | 43 | 16 | 37,2% | 14 | 32,6% | 13 | 30,2% | |
LAP+ | 17 | 5 | 29,4% | 8 | 47,1% | 4 | 23,5% | |
Total | 359 | 96 | 26,7% | 185 | 51,5% | 78 | 21,7% | |
CT IgG- | LCx+ (CT DNA+) | 49 | 15 | 30,6% | 23 | 46,9% | 11 | 22,4% |
MO+ | 16 | 3 | 18,8% | 10 | 62,5% | 3 | 18,8% | |
Symp | 19 | 5 | 26,3% | 11 | 57,9% | 3 | 15,8% | |
LAP+ | 10 | 3 | 30,0% | 6 | 60,0% | 1 | 10,0% | |
LCx- (CT DNA-) | 310 | 81 | 26,1% | 162 | 52,3% | 67 | 21,6% | |
MO+ | 88 | 20 | 22,7% | 53 | 60,2% | 15 | 17,0% | |
Symp | 103 | 26 | 25,2% | 51 | 49,5% | 26 | 25,2% | |
LAP+ | 37 | 6 | 16,2% | 20 | 54,1% | 11 | 29,7% | |
Healthy Controls | 170 | 48 | 28,2% | 82 | 48,2% | 40 | 23,5% | |